EP3694556A1 — Formulations comprising 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazab icyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
Assigned to Loxo Oncology Inc · Expires 2020-08-19 · 6y expired
What this patent protects
The present invention relates to 6- (2-hydroxy-2-methylpropoxy) -4- (6- (6 - ((6-methoxypyridin-3-yl) methyl) -3,6-diazabicyclo [3.1.1] heptan- 3-yl) pyridin-3-yl) pyrazolo [1,5-a] pyridine-3-carbonitrile, or an associated pharmaceutically acceptable salt, an amorphous form, a po…
USPTO Abstract
The present invention relates to 6- (2-hydroxy-2-methylpropoxy) -4- (6- (6 - ((6-methoxypyridin-3-yl) methyl) -3,6-diazabicyclo [3.1.1] heptan- 3-yl) pyridin-3-yl) pyrazolo [1,5-a] pyridine-3-carbonitrile, or an associated pharmaceutically acceptable salt, an amorphous form, a polymorphic form or a pharmaceutical composition (including solid formulations or formulations liquid) and their use for the treatment of diseases and disorders that can be treated with a RET kinase inhibitor, such as diseases and disorders associated with RET, for example, proliferative disorders such as cancers, especially hematologic malignancies. and solid tumors, and gastrointestinal disorders such as irritable bowel syndrome.
Drugs covered by this patent
- Retevmo (SELPERCATINIB) · Eli Lilly
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.